Genetic Disorders and Biochemical Pathology Practice Questions

Q: In individuals of South Indian descent with a family history of type 2 diabetes, which genetic variant is most commonly associated with an increased risk of developing this condition?

TCF7L2 gene variant. ***TCF7L2 gene variant*** - The **TCF7L2 gene variant** is consistently identified as the strongest genetic risk factor for **Type 2 Diabetes (T2DM)** across various populations, including South Indians, due to its role in **insulin secretion** and **glucose homeostasis**. - Its association with increased T2DM risk is particularly significant in individuals with a **family history**, highlighting its broad impact on genetic predisposition. *SLC30A8 gene variant* - The **SLC30A8 gene** encodes a **zinc transporter** in pancreatic beta cells and is also associated with T2DM risk. - While relevant, its effect size and prevalence as a primary risk factor are generally less pronounced compared to TCF7L2, particularly in the South Indian population where TCF7L2 shows stronger association. *PPAR-gamma gene variant* - **PPAR-gamma** is involved in **adipogenesis** and **insulin sensitivity**, and variants in this gene are associated with T2DM and metabolic syndrome. - However, the **TCF7L2 gene** has consistently shown a stronger and more prevalent association with T2DM risk in the general population, including South Indians, compared to PPAR-gamma variants. *KCNJ11 gene variant* - The **KCNJ11 gene** encodes a subunit of the **ATP-sensitive potassium channel** in pancreatic beta cells, crucial for insulin secretion. Variants in this gene are linked to monogenic forms of diabetes, such as **Neonatal Diabetes Mellitus** and **Maturity-Onset Diabetes of the Young (MODY)**. - While it plays a role in glucose metabolism, its contribution to the common polygenic form of **Type 2 Diabetes** is less significant than that of TCF7L2, and it is not typically cited as the most common genetic risk factor in a broad population context like South Indians with a family history of T2DM.

Q: A patient is diagnosed with MELAS syndrome after presenting with stroke-like episodes and lactic acidosis. What is the underlying defect?

Mitochondrial DNA mutation. ***Mitochondrial DNA mutation*** - **MELAS syndrome** (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) is specifically caused by mutations in **mitochondrial DNA (mtDNA)**. - These mutations impair the function of the **mitochondrial respiratory chain**, leading to energy production deficits in high-energy demand tissues like the brain and muscles. *Nuclear DNA mutation* - While many genetic disorders are caused by nuclear DNA mutations, **MELAS** is distinctly characterized by its mode of inheritance and origin in the **mitochondrial genome**. - **Nuclear DNA mutations** cause problems in a vast array of cellular functions, but not the specific triad of MELAS symptoms with mtDNA inheritance. *Lysosomal storage defect* - **Lysosomal storage diseases** involve enzyme deficiencies that lead to the accumulation of specific substrates within lysosomes. - These typically present with organomegaly, skeletal abnormalities, and neurodegeneration, but not the stroke-like episodes and lactic acidosis seen in MELAS. *Glycogen storage disease* - **Glycogen storage diseases** are characterized by enzyme defects in glycogen synthesis or breakdown, leading to abnormal glycogen accumulation or depletion. - Clinical features usually include hypoglycemia, hepatomegaly, and myopathy, which differ from the primary neurological and metabolic symptoms of MELAS.

Q: How does a defect in the enzyme 21-hydroxylase affect the synthesis of adrenal hormones?

Decreases aldosterone and cortisol synthesis. ***Decreases aldosterone and cortisol synthesis*** - 21-hydroxylase is a crucial enzyme in the adrenal steroid synthesis pathway, necessary for converting **progesterone** to **11-deoxycorticosterone** (a precursor to aldosterone) and **17-hydroxyprogesterone** to **11-deoxycortisol** (a precursor to cortisol). - A defect in this enzyme directly impairs the production of both **cortisol** and **aldosterone**, leading to their deficiency. - This is the hallmark of **congenital adrenal hyperplasia (CAH)** due to 21-hydroxylase deficiency. *Decreases cortisol production* - While cortisol production is decreased, this option is incomplete as it fails to mention the concurrent decrease in **aldosterone** synthesis, which is also a significant consequence of 21-hydroxylase deficiency. - The deficiency impacts multiple steroid pathways, not just the cortisol pathway in isolation. *Leads to decreased estrogen production* - Estrogen synthesis primarily occurs in the **gonads** and **peripheral tissues** from androgens, not directly regulated by 21-hydroxylase in the adrenal cortex. - A 21-hydroxylase defect leads to an **accumulation of androgen precursors** (like DHEA), which can be converted to estrogens peripherally, sometimes even increasing estrogen levels in certain forms of congenital adrenal hyperplasia. *Decreases androgen synthesis* - This is **incorrect** - a 21-hydroxylase defect causes a shunting of precursors towards the **androgen pathway**, leading to an **increase in androgen synthesis**, not a decrease. - This excess androgen production is responsible for the **virilization** observed in individuals with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, including ambiguous genitalia in females and precocious puberty in males.

Q: Which enzyme deficiency leads to the accumulation of ceramide trihexoside in Fabry disease?

α-galactosidase A deficiency. ***α-galactosidase A deficiency*** - **Fabry disease** is an **X-linked recessive** lysosomal storage disorder caused by a deficiency of the enzyme **α-galactosidase A**. - This enzyme deficiency leads to the accumulation of its substrate, **globotriaosylceramide (Gb3)**, also known as **ceramide trihexoside**, in various tissues. *β-glucosidase deficiency* - This deficiency is characteristic of **Gaucher disease**, leading to the accumulation of **glucocerebroside**. - Patients typically present with **hepatosplenomegaly**, **bone pain**, and **pancytopenia**, which are not features of Fabry disease. *Hexosaminidase A deficiency* - This enzyme deficiency is associated with **Tay-Sachs disease**, which results in the accumulation of **GM2 gangliosides**. - Tay-Sachs disease primarily affects the **nervous system**, causing neurodegeneration in infancy. *Sphingomyelinase deficiency* - This deficiency causes **Niemann-Pick disease**, leading to the accumulation of **sphingomyelin** in lysosomes. - Clinical features include **hepatosplenomegaly**, **neurodegeneration** (especially in Type A), and characteristic **foam cells**.

Q: Which enzyme deficiency is associated with Lesch-Nyhan syndrome, which is characterized by self-mutilation and hyperuricemia?

Hypoxanthine-guanine phosphoribosyltransferase. ***Hypoxanthine-guanine phosphoribosyltransferase*** - Deficiency of **hypoxanthine-guanine phosphoribosyltransferase (HGPRT)** leads to an inability to salvage purines, resulting in their degradation to **uric acid**. - This overproduction of uric acid causes **hyperuricemia** and characteristic neurological symptoms, including **self-mutilation**, choreoathetosis, and cognitive dysfunction, defining Lesch-Nyhan syndrome. *Adenosine deaminase* - Deficiency in **adenosine deaminase (ADA)** leads to the accumulation of **adenosine** and **deoxyadenosine**, which are toxic to lymphocytes. - This causes severe combined immunodeficiency **(SCID)**, not Lesch-Nyhan syndrome. *Xanthine oxidase* - **Xanthine oxidase** is involved in the catabolism of purines, converting hypoxanthine to xanthine and then to uric acid. - Its deficiency leads to **xanthinuria**, characterized by low uric acid levels and **xanthine kidney stones**, which is distinct from Lesch-Nyhan syndrome. *Phosphoribosyl pyrophosphate synthetase* - **Phosphoribosyl pyrophosphate (PRPP) synthetase** is involved in the *de novo* purine synthesis pathway. - Overactivity (not deficiency) of this enzyme can lead to increased purine production and **hyperuricemia**, but a deficiency typically impairs purine synthesis and does not present with Lesch-Nyhan features.

Q: Which enzyme deficiency leads to the accumulation of homogentisic acid, resulting in dark urine and ochronosis?

Homogentisate oxidase. ***Homogentisate oxidase*** - Deficiency of **homogentisate oxidase** is the underlying cause of **alkaptonuria**, a rare genetic disorder. - This enzyme is crucial for the metabolism of **tyrosine**, and its absence leads to the accumulation of **homogentisic acid**, which is excreted in the urine and oxidizes upon exposure to air, turning it dark. *Phenylalanine hydroxylase* - Deficiency in **phenylalanine hydroxylase** causes **phenylketonuria (PKU)**, leading to the accumulation of phenylalanine. - PKU primarily results in neurodevelopmental issues and intellectual disability if untreated, not dark urine or ochronosis. *Tyrosine hydroxylase* - **Tyrosine hydroxylase** is involved in the synthesis of catecholamines (dopamine, norepinephrine, epinephrine). - Its deficiency leads to a shortage of these neurotransmitters, causing neurological symptoms but not the characteristic features of alkaptonuria. *Fumarylacetoacetate hydrolase* - Deficiency of **fumarylacetoacetate hydrolase** causes **tyrosinemia type I**, a severe metabolic disorder. - This condition results in liver and kidney damage, neurological crises, and a characteristic "cabbage-like" odor, distinct from the symptoms of alkaptonuria.

Q: A newborn exhibits severe mental retardation and a musty body odor. What is the likely diagnosis based on these clinical features?

Phenylketonuria. ***Phenylketonuria*** - **Phenylketonuria (PKU)** is an autosomal recessive disorder characterized by the inability to metabolize **phenylalanine**, leading to its accumulation. - Classic symptoms in untreated individuals include **severe intellectual disability**, **seizures**, and a distinct **musty body odor** due to the accumulation of phenylacetic acid. *Alkaptonuria* - This disorder is characterized by the accumulation of **homogentisic acid**, which leads to **dark urine** upon standing and bluish-black pigmentation of cartilage and connective tissues (**ochronosis**). - It does not typically present with severe mental retardation or a musty body odor in infancy. *Maple syrup urine disease* - This metabolic disorder is characterized by the inability to metabolize **branched-chain amino acids** (leucine, isoleucine, and valine), leading to their accumulation. - Key features include neurological damage, feeding difficulties, and a characteristic **sweet, maple syrup-like odor in urine** and earwax, not a musty odor. *Homocystinuria* - This is a disorder of methionine metabolism, leading to the accumulation of **homocysteine** in the blood and urine. - Clinical features include **ectopia lentis** (dislocation of the lens), skeletal abnormalities, thrombotic events, and **developmental delay** or intellectual disability, but not a musty body odor.

Q: What is the biochemical effect of a deficiency in the enzyme hexosaminidase A on ganglioside metabolism?

Accumulation of GM2 ganglioside due to impaired degradation. ***Accumulation of GM2 ganglioside due to impaired degradation*** - Hexosaminidase A is responsible for the catabolism of **GM2 ganglioside** by removing the terminal N-acetylgalactosamine. - Deficiency leads to the **lysosomal accumulation** of GM2 ganglioside, primarily in neural tissues, causing neurodegeneration. *No change in sphingomyelin synthesis* - Sphingomyelin synthesis and degradation are primarily managed by **sphingomyelinase**, an enzyme distinct from hexosaminidase A. - A deficiency in hexosaminidase A specifically affects **ganglioside metabolism**, not sphingomyelin. *No significant change in ceramide production* - Ceramide is a precursor to many sphingolipids, including gangliosides, and its production is upstream of ganglioside catabolism. - Hexosaminidase A deficiency impacts the **degradation of specific gangliosides**, not the synthesis of ceramide. *Impaired glycolipid degradation without specific accumulation* - Hexosaminidase A deficiency leads to a **very specific accumulation** (GM2 ganglioside), not a general, non-specific impairment of glycolipid degradation. - The disease associated with this deficiency (Tay-Sachs disease) is characterized by this **particular lipid storage**.

Question 1

In individuals of South Indian descent with a family history of type 2 diabetes, which genetic variant is most commonly associated with an increased risk of developing this condition?

Accepted Answer

TCF7L2 gene variant

Answer

SLC30A8 gene variant

Answer

PPAR-gamma gene variant

Answer

KCNJ11 gene variant

Question 2

A patient is diagnosed with MELAS syndrome after presenting with stroke-like episodes and lactic acidosis. What is the underlying defect?

Accepted Answer

Mitochondrial DNA mutation

Answer

Nuclear DNA mutation

Answer

Lysosomal storage defect

Answer

Glycogen storage disease

Question 3

How does a defect in the enzyme 21-hydroxylase affect the synthesis of adrenal hormones?

Accepted Answer

Decreases aldosterone and cortisol synthesis

Answer

Decreases androgen synthesis

Answer

Decreases cortisol production

Answer

Leads to decreased estrogen production

Question 4

Which enzyme deficiency leads to the accumulation of ceramide trihexoside in Fabry disease?

Accepted Answer

α-galactosidase A deficiency

Answer

β-glucosidase deficiency

Answer

Hexosaminidase A deficiency

Answer

Sphingomyelinase deficiency

Question 5

Which enzyme deficiency is associated with Lesch-Nyhan syndrome, which is characterized by self-mutilation and hyperuricemia?

Accepted Answer

Hypoxanthine-guanine phosphoribosyltransferase

Answer

Adenosine deaminase

Answer

Xanthine oxidase

Answer

Phosphoribosyl pyrophosphate synthetase

Question 6

Which enzyme deficiency leads to the accumulation of homogentisic acid, resulting in dark urine and ochronosis?

Accepted Answer

Homogentisate oxidase

Answer

Phenylalanine hydroxylase

Answer

Tyrosine hydroxylase

Answer

Fumarylacetoacetate hydrolase

Question 7

A 50-year-old woman with progressive ataxia is found to have an autosomal recessive mutation affecting the frataxin gene. Which of the following best describes a key aspect of the pathophysiology of her condition?

Accepted Answer

Impaired mitochondrial iron handling due to frataxin deficiency.

Answer

Increased oxidative stress resulting from mitochondrial dysfunction.

Answer

Decreased ATP synthesis due to impaired iron metabolism.

Answer

Progressive neuronal degeneration in the dorsal root ganglia.

Question 8

A newborn exhibits severe mental retardation and a musty body odor. What is the likely diagnosis based on these clinical features?

Accepted Answer

Phenylketonuria

Answer

Alkaptonuria

Answer

Maple syrup urine disease

Answer

Homocystinuria

Question 9

What is the biochemical effect of a deficiency in the enzyme hexosaminidase A on ganglioside metabolism?

Accepted Answer

Accumulation of GM2 ganglioside due to impaired degradation

Answer

No change in sphingomyelin synthesis

Answer

No significant change in ceramide production

Answer

Impaired glycolipid degradation without specific accumulation

Question 10

What is the underlying biochemical defect in phenylketonuria (PKU) that leads to cognitive impairment if left untreated?

Accepted Answer

Deficiency in phenylalanine hydroxylase, leading to accumulation of phenylalanine

Answer

Deficiency in tyrosinase, leading to lack of melanin production

Answer

Deficiency in homogentisate oxidase, leading to ochronosis

Answer

Deficiency in glucose-6-phosphatase, leading to hypoglycemia

Genetic Disorders and Biochemical Pathology — MCQs

Genetic Disorders and Biochemical Pathology — MCQs

On this page

Practice by Chapter

Want unlimited practice?